Skip to content

Inhibrx Biosciences, Inc. INBX Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement

Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement at other companies

Nextdoor Holdings, Inc. logo
Nextdoor Holdings, Inc.NXDR
$0-100%
Lyft, Inc. logo
Lyft, Inc.LYFT
-$3.66M-618%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0-100%
Andersen Group
 logo
Andersen Group ANDG
-$437.75K
Maplebear Inc. logo
Maplebear Inc.CART
$4.25M+1,600%
Eastern Bankshares, Inc. logo
Eastern Bankshares, Inc.EBC
$2.46M+48.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement.

The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement?
Inhibrx Biosciences, Inc. (INBX) reported remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement of $0 in Q4 2025.
How has Inhibrx Biosciences, Inc.'s remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement changed year-over-year?
Inhibrx Biosciences, Inc.'s remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement decreased by 100.0% year-over-year, from $6.3M to $0.
What does remeasurement of operating lease liability and right-of-use asset in connection with 2024 lease agreement mean?
This reflects the non-cash adjustments made to the carrying value of operating lease liabilities and corresponding right-of-use assets due to lease modifications or changes in estimates. These adjustments are non-cash in nature and are excluded from operating cash flow calculations to provide a clearer view of actual cash burn. Frequent remeasurements may suggest significant changes in the company's physical footprint or lease portfolio strategy.